ES2191007T3 - Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos. - Google Patents

Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.

Info

Publication number
ES2191007T3
ES2191007T3 ES92924163T ES92924163T ES2191007T3 ES 2191007 T3 ES2191007 T3 ES 2191007T3 ES 92924163 T ES92924163 T ES 92924163T ES 92924163 T ES92924163 T ES 92924163T ES 2191007 T3 ES2191007 T3 ES 2191007T3
Authority
ES
Spain
Prior art keywords
tgf
beta
codifies
type iii
receiver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924163T
Other languages
English (en)
Inventor
Herbert Y Lin
Xiao-Fan Wang
Robert A Weinberg
Harvey F Lodish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25137484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2191007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Application granted granted Critical
Publication of ES2191007T3 publication Critical patent/ES2191007T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTAN UN DNA QUE CODIFICA UN RECEPTOR DEL TGF-(BETA) DEL TIPO III DE ORIGEN MAMIFERO, UN DNA QUE CODIFICA UN RECEPTOR DE TGF-(BETA) DE TIPO II DE ORIGEN MAMIFERO, UN RECEPTOR DE TGF-(BETA) DE TIPO III, Y UN RECEPTOR DEL TGF-(BETA) DE TIPO II Y USOS DE LOS MISMOS.
ES92924163T 1991-10-31 1992-10-30 Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos. Expired - Lifetime ES2191007T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78606391A 1991-10-31 1991-10-31

Publications (1)

Publication Number Publication Date
ES2191007T3 true ES2191007T3 (es) 2003-09-01

Family

ID=25137484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924163T Expired - Lifetime ES2191007T3 (es) 1991-10-31 1992-10-30 Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.

Country Status (9)

Country Link
US (7) US6010872A (es)
EP (2) EP1149908A1 (es)
JP (2) JP4124815B2 (es)
AU (1) AU671606B2 (es)
CA (1) CA2122491A1 (es)
DE (1) DE69232986T2 (es)
ES (1) ES2191007T3 (es)
HK (1) HK1040744A1 (es)
WO (1) WO1993009228A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
DE69332026T2 (de) * 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
WO1995006656A1 (en) * 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5780436A (en) * 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DK1223990T3 (da) 1999-10-15 2004-11-29 Inst Genetics Llc Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
AU2003209308A1 (en) * 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
US8058077B2 (en) * 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
JP4543189B2 (ja) * 2004-03-10 2010-09-15 学校法人日本医科大学 ＴＧＦβ１レセプターＩＩ型に対するＲＮＡｉとして作用するＲＮＡ配列
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP4706193B2 (ja) * 2004-05-27 2011-06-22 国立大学法人 長崎大学 マルファン症候群の分析のためのプローブの使用、スクリーニング方法およびキット
WO2006044433A2 (en) * 2004-10-13 2006-04-27 The Ohio State University Research Foundation Methods to treat or prevent viral-associated lymphoproliferative disorders
JP2007043918A (ja) * 2005-08-08 2007-02-22 Medeinetto:Kk 腫瘍成長因子β受容体発現細胞株
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2009152610A1 (en) * 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
JP2011045339A (ja) * 2009-08-28 2011-03-10 Univ Of Tokyo ＴＧＦ−βＩＩ型受容体に結合する核酸およびその使用
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
LT2971048T (lt) 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
MY202480A (en) 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof
MX2020009272A (es) 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
US12559539B2 (en) 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN114391021B (zh) 2019-06-21 2026-01-16 凯德药业股份有限公司 TGF-β受体和使用方法
CN113968903A (zh) 2020-07-24 2022-01-25 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
WO2022261061A1 (en) 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
DE69332026T2 (de) * 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel

Also Published As

Publication number Publication date
JPH07501212A (ja) 1995-02-09
US6086867A (en) 2000-07-11
US20060247198A1 (en) 2006-11-02
HK1040744A1 (en) 2002-06-21
US20050260579A1 (en) 2005-11-24
DE69232986T2 (de) 2003-12-11
US6046157A (en) 2000-04-04
AU671606B2 (en) 1996-09-05
DE69232986D1 (de) 2003-05-08
US20080234216A1 (en) 2008-09-25
JP2006055164A (ja) 2006-03-02
WO1993009228A1 (en) 1993-05-13
US6010872A (en) 2000-01-04
JP4185512B2 (ja) 2008-11-26
US6201108B1 (en) 2001-03-13
JP4124815B2 (ja) 2008-07-23
AU3057892A (en) 1993-06-07
CA2122491A1 (en) 1993-05-13
EP1149908A1 (en) 2001-10-31
EP0610427A1 (en) 1994-08-17
EP0610427B1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
ES2191007T3 (es) Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.
ES2022873B3 (es) Termoplasticos de ingenieria que contienen grupos de benzociclobuteno unidos.
NO874489L (no) Bicykliske forbindelser.
ES2111031T3 (es) Uso de preparaciones que contienen anticuerpos para la inmunosupresion.
DE3789206D1 (de) Pendelrückkopplungs-Detektor.
DK0467026T3 (da) Middel til farvning af hår og anvendelse af midlet
ES511428A0 (es) Un receptor optico.
DE3776159D1 (de) Feuerdetektor.
NL183733C (nl) Verbindingsmof.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
IT8523318A0 (it) Circuito rivelatore di inquadramento pseudo-casuale.
DE3778081D1 (de) Schnellverschlussmuffe.
DE3765852D1 (de) Schlauchfoermige verpackungshuelle.
DE3788585D1 (de) Flüssige Brennstoffzusammensetzungen.
DE3782773D1 (de) Fluessige brennstoffzusammensetzungen.
NO873816L (no) Tricykliske forbindelser.
DE3773321D1 (de) Fasswaage.
FI873163A7 (fi) Tukilaite kranaatinheittimen putkea varten.
MX9303444A (es) Polinucleotidos aislados que codifican para una familia de receptores del sistema nervioso central humano.
MX9101435A (es) Sistema de comunicacion submarina con uso del medio ambiente fisico
DE3764919D1 (de) Haertbare zusammensetzung.
DE3774914D1 (de) Schnellkupplung fuer fallschirm.
DE3779991D1 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
ES257028Y (es) Ampolla de inyeccion de un solo uso.
DE68903162D1 (de) Reaktionsgefaess.